Immunotherapy / PD-L1 inhibitorFDA-approvedSecond-line
Tecentriq
Generic name: atezolizumab
How it works
Blocks the PD-L1 receptor on cancer cells, allowing immune cells to attack them.
Cancer types
Lung Cancer— PD-L1-positive
Efficacy
In clinical trials, atezolizumab improved overall survival in patients with non-small cell lung cancer, with a median overall survival of approximately 13.3 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Cabozantinib and Atezolizumab for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Atezolizumab Treatment for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Atezolizumab and Sacituzumab Govitecan to Prevent Triple Negative Breast Cancer Recurrence | Breast Cancer | phase-2 | — | Source → |
| Researchers Identify Potential Blood-Based Biomarkers for Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Testing Atezolizumab and Capecitabine for Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Rectal Cancer Treatment Trial Investigates Atezolizumab and Tiragolumab | Colorectal Cancer | phase-2 | — | Source → |
| Testing Natural Killer Cells and Atezolizumab for Acute Myelogenous Leukemia | Leukemia | phase-1 | — | Source → |
| New Way to Give Cancer Treatment May Be Easier for Patients | Lung Cancer | phase-1/2 | A fixed 1,875-mg SC dose every 3 weeks provides bioavailability and steady-state exposure non-inferior to IV. | Source → |
| Study of Atezolizumab, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer with Brain Metastases | Breast Cancer | phase-2 | — | Source → |
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 9.93 months for pembrolizumab and 5.33 months for atezolizumab. | Source → |
| New Treatment Combination Shows Promise for Colon Cancer Patients | Colorectal Cancer | phase-3 | The 3-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group, as compared with 76.2% in the mFOLFOX6 group. | Source → |
| Tracking Cancer Evolution with Liquid Biopsy | Lung Cancer | lab-study | — | Source → |
| Real-world effectiveness of adjuvant atezolizumab in lung cancer patients | Lung Cancer | observational | The 2-year disease-free survival rate was 63.8%. | Source → |
| New Cancer Treatment Shows Promise in Lab Experiments | Melanoma | lab-study | — | Source → |
| Atezolizumab plus chemotherapy effective in Japanese patients with advanced lung cancer | Lung Cancer | observational | Twelve-month OS rates were 62.9% (atezo + CnP), 72.1% (atezo + PP), and 68.3% (atezo + bev + CP). | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Atezolizumab Monotherapy Window in Triple-Negative Breast Cancer | Breast Cancer | phase-2 | pCR rates in study arms A and B were similar (65.7% and 69.0%, respectively). | Source → |
| Cost-effectiveness of Atezolizumab for Lung Cancer Patients | Lung Cancer | phase-3 | Adding atezolizumab to chemotherapy increased QALYs by 0.721 at an incremental cost of NT$2,111,359. | Source → |
| Combining Two Treatments May Help Fight Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Atezolizumab Compared to Docetaxel in Lung Cancer Treatment | Lung Cancer | meta-analysis | Atezolizumab had better efficacy than docetaxel for overall survival (HR: 0.77, 95% CI: 0.73 to 0.81). | Source → |
| Atezolizumab treatment may worsen eye problems in some lung cancer patients | Lung Cancer | observational | — | Source → |
| New Cancer Treatment Combination Shows Promise for Melanoma Patients | Melanoma | phase-2 | 12-month EFS was 72.0% (95%CI 57.9-89.5%), 12-month RFS was 73.3% (95%CI 56.9-94.5%), and 12-month DMFS 86.0% (95%CI 72.2-100%). | Source → |
| New Treatment Option for Advanced Lung Cancer Patients | Lung Cancer | phase-3 | Atezolizumab improved OS compared to monochemotherapy. | Source → |
| Atezolizumab May Increase Risk of Severe Blood Infections in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| New Treatment Combination Shows Promise for Rare Cancer | Leukemia | phase-2 | — | Source → |
| New Lung Cancer Treatment Shows Promise in Early Study | Lung Cancer | phase-3 | The median overall survival was 10.7 months, and the median progression-free survival was 5.5 months. | Source → |
| Elderly Lung Cancer Patients Treated with Atezolizumab | Lung Cancer | phase-2 | — | Source → |
| New Options for Lung Cancer Treatment After Surgery | Lung Cancer | phase-3 | Improved disease-free survival and, in case of PD-L1 at least 50%, also improved overall survival for atezolizumab compared to best supportive care. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.